Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Feb;43(2):74-8.
doi: 10.1016/j.exphem.2014.10.009. Epub 2014 Oct 28.

Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism

Wade T Iams  1 , Megan L Hames  2 , Judy P Tsai  3 , Kimberly B Dahlman  4 , Mahsa S Talbott  2 , Kristy L Richards  5 , Nishitha M Reddy  6
Affiliations
Clinical Trial

Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism

Wade T Iams et al. Exp Hematol. 2015 Feb.

Abstract

As the use of lenalidomide expands, the poorly understood phenomenon of lenalidomide-induced thyroid abnormalities will increase. In this study, we compared rates of therapy-induced hypothyroidism in 329 patients with diffuse large B-cell lymphoma (DLBCL) treated with conventional chemotherapy (DLBCL-c) or conventional chemotherapy plus lenalidomide (DLBCL-len). We measured serum levels of tumor necrosis factor α, interferon gamma, interleukin 6, interleukin 12, and interleukin 15 before and after treatment. We found a significantly higher rate of therapy-induced hypothyroidism in the DLBCL-len group (25.8% vs. 1.3%), and we found a statistically significant increase in serum tumor necrosis factor α in patients with lenalidomide-induced hypothyroidism.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflict of Interest: NMR; advisory board and research funding: Celgene

Figures

Figure 1
Figure 1
a–c: 1a- serum cytokine levels pre and post lenalidomide based therapy (n=27). 1bserum cytokine levels pre and post lenalidomide alone (n=27). 1c-serum cytokine levels pre and post lenalidomide with rituximab (n=27).
Figure 2
Figure 2
a–c: 2a- TNFα levels of all patients pre and post lenalidomide based treatment who developed worsening hypothyroidism (n=10), P=0.002 (95% CI 4.21–9.03). 2b-TNFα levels pre and post lenalidomide who developed worsening hypothyroidism (n=6), P=0.0053 (95% CI 3.07–10.48). 2c- TNFα of patients treated with lenalidomide and rituximab who developed worsening hypothyroidism (n=4),
See this image and copyright information in PMC

References

    1. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4952–4957. - PubMed
    1. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22:1622–1627. - PubMed
    1. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117:5058–5066. - PubMed
    1. Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27:1902–1909. - PubMed
    1. Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11:462–466. - PubMed

Publication types

MeSH terms